SEARCH

SEARCH BY CITATION

References

  • 1
    Marron DJ & Fazio S. Current perspectives on statins. Circulation 2000; 101: 20713.
  • 2
    Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New England J Med 1999; 341: 4108.
  • 3
    Schwandt P. Drug interactions and side effect of hypolipidemic drugs. Int J Clin Pharmacol Biopharm 1979; 17: 3516.
  • 4
    Hamelin BA & Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 2637.
  • 5
    Benichou C. Criteria of drug-induced liver disorders. Report of an international concensus meeting. J Hepatol 1990; 11: 2726.
  • 6
    Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Progressi Med 1991; 82: 2335.
  • 7
    Ballare M, Campanini M, Airoldi G et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterologica e Dietologica 1992; 38: 414.
  • 8
    Feydy P & Bogomoletz WV. Un cas d’hepatite a la simvastatine. Gastroenterol Clin Biol 1991; 15: 945.
  • 9
    Roblin X, Becot F, Piquemal A, Baziz A. Hepatite a la simvastatine. Gastroenterol Clin Biol 1992; 16: 101101.
  • 10
    Hartleb M, Rymarczyk G, Januszcwski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999; 94: 138890.
    Direct Link:
  • 11
    Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin [Letter]. Lancet 1999; 353: 17634.
  • 12
    Gavilan Carrasco JC, Bermudez Reclo F, Saldago Ordonez F, Gonzalez Santos P. Hepatitis inducida por lovastatina. Med Clinica 1996; 14: 5778.
  • 13
    Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994; 39: 20323.
  • 14
    Hachzermeyer H & Muenzenmaier R. Lovastatin-induzierte akute cholestatische hepatitis. Dtsch Med Wschr 1995; 120: 2526.
  • 15
    Dumortier J, Slim R, Chevallier M et al. Hepatite aigue severe cirrhogene apres prise de ciprofibrate. Gastroenterol Clin Biol 1999; 23: 1399400.
  • 16
    Bernard P-H, Lamouliatte H, Le Bail B, Bioulac-Sage P, Quinton A, Balabaud C. Hepatite chronique active associee a des anticorps anti-noyau induite par le fenofibrate. Gastroenterol Clin Biol 1994; 18: 10489.
  • 17
    Chatrenet P, Regimbeau C, Ramain J-P, Penot J, Bruandet P. Hepatite chronique active cirrhogene au fenofibrate. Gastroenterol Clin Biol 1993; 17: 6123.
  • 18
    Ganne-Carrie N, Leusse A, Guettier C et al. Hepatites d’allure auto-immune induites par les fibrates. Gastroenterol Clin Biol 1998; 22: 5259.
  • 19
    Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 7116.